abstract |
The present invention relates to a method for diagnosing or prognosing metastasis in lung cancer, comprising determining whether the c-MAF gene is amplified in a primary tumor sample. In addition, the present invention relates to a method of measuring a tendency to cause bone metastasis compared to metastasis in other organs, comprising not only a method of diagnosing or prognosing metastasis in lung cancer, but also measuring the c-MAF gene expression level. . Finally, the present invention relates to the use of c-MAF inhibitors as therapeutic targets for treating lung cancer. |